| Name | Title | Contact Details |
|---|
MarketFirst Software is a Mountain View, CA-based company in the Software and Internet sector.
Experience the most powerful legal research and analytics platform
Ellation, Inc. is a transformative entertainment company and home of industry-leading brands Crunchyroll, Rooster Teeth, and VRV. As part of Otter Media, a WarnerMedia company, Ellation operates at the intersection of technology and media to redefine the next wave of media interaction and consumption -- breaking down barriers to content experiences for passionate fans around the world. Ellations offices in San Francisco, Los Angeles, Austin, Chișinău, and Tokyo develop the product, design, engineering, marketing and content that brings our communities of passionate fans together.
Based at Sacramento, California, tab32 is the industry`s No 1 technology platform for dental electronic health records (dental DEM) software, dental practice management system (dental SPM) and open data warehousing. Providers use tab32 to track 9.3 million appointments, 7.3 million patients, and over 100 million x-rays, with over 1 million monthly patient commitments and $ 375 million annual income passing through the platform. The all-in-one cloud platform delivers comprehensive and engaging patient experiences across the care value chain, enabling dental practices to achieve long-term sustainable growth and profitability. With a management team of former researchers, data scientists and engineers from University of california, tab32 has pioneered many innovations in the market such as integrated text messaging, VoIP, electronic forms, mobile payments, cloud imaging and a standard model for open data sharing in the dental field.
Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.